Liquidia (NASDAQ:LQDA) Stock Price Down 3.3% - Should You Sell?

Liquidia Co. (NASDAQ:LQDA - Get Free Report)'s share price dropped 3.3% on Tuesday . The stock traded as low as $16.30 and last traded at $16.31. Approximately 198,042 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 1,098,639 shares. The stock had previously closed at $16.87.

Analysts Set New Price Targets

A number of research firms recently commented on LQDA. Wells Fargo & Company upped their price objective on Liquidia from $20.00 to $23.00 and gave the company an "overweight" rating in a report on Wednesday, May 28th. Raymond James upped their price objective on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Needham & Company LLC restated a "buy" rating on shares of Liquidia in a research note on Monday, June 2nd. Scotiabank increased their target price on Liquidia from $36.00 to $37.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, May 28th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Liquidia in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Liquidia has an average rating of "Moderate Buy" and a consensus price target of $26.67.

Liquidia Stock Performance

The company has a market cap of $1.55 billion, a price-to-earnings ratio of -11.13 and a beta of 0.24. The business has a 50-day simple moving average of $14.97 and a 200-day simple moving average of $14.00.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. Research analysts anticipate that Liquidia Co. will post -1.51 EPS for the current year.

Insider Buying and Selling at Liquidia

In other news, General Counsel Russell Schundler sold 5,964 shares of the business's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $80,931.48. Following the completion of the sale, the general counsel now owns 570,301 shares in the company, valued at approximately $7,738,984.57. The trade was a 1.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jason Adair sold 1,856 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. The trade was a 1.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,138 shares of company stock worth $450,233 over the last ninety days. Corporate insiders own 26.50% of the company's stock.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently made changes to their positions in LQDA. Rhumbline Advisers lifted its holdings in shares of Liquidia by 3.5% in the 4th quarter. Rhumbline Advisers now owns 80,652 shares of the company's stock valued at $948,000 after purchasing an additional 2,741 shares during the last quarter. Sigma Planning Corp increased its position in Liquidia by 3.4% during the fourth quarter. Sigma Planning Corp now owns 65,210 shares of the company's stock worth $767,000 after buying an additional 2,115 shares during the period. Bank of New York Mellon Corp increased its position in Liquidia by 3.3% during the fourth quarter. Bank of New York Mellon Corp now owns 188,584 shares of the company's stock worth $2,218,000 after buying an additional 6,034 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in Liquidia in the fourth quarter valued at approximately $59,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Liquidia by 9.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company's stock valued at $5,040,000 after acquiring an additional 38,313 shares during the period. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).